Efficacy and Safety of Anti–Interleukin‐20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial

Objective Interleukin‐20 (IL‐20) is implicated in the pathogenesis of rheumatoid arthritis (RA). The efficacy, safety, and tolerability of NNC0109‐0012, a selective anti–IL‐20 recombinant human monoclonal antibody (mAb), were assessed in patients with active RA who had an inadequate response to meth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2015-06, Vol.67 (6), p.1438-1448
Hauptverfasser:	Šenolt, Ladislav, Leszczynski, Piotr, Dokoupilová, Eva, Göthberg, Marie, Valencia, Xavier, Hansen, Brian Bekker, Cañete, Juan D.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antibodies, Monoclonal - therapeutic use Antibodies, Neutralizing - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - immunology Autoantibodies - immunology C-Reactive Protein - immunology Cytokines Double-Blind Method Female Herpes Simplex - chemically induced Humans Interleukins - antagonists & inhibitors Male Medical treatment Middle Aged Nasopharyngitis - chemically induced Peptides, Cyclic - immunology Respiratory Tract Infections - chemically induced Rheumatism Rheumatoid arthritis Rheumatoid Factor - immunology Treatment Outcome Urinary Tract Infections - chemically induced Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!